NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
Articles by Natasha Yetman
According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA
NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….
Even with Insurance, Fewer Americans Seeing Primary Care Providers
(Reuters Health)—Almost half of U.S. adults with private health insurance are not visiting primary care providers for routine care or sick visits, a new study suggests. Between 2008 and 2016, the number of annual primary care visits for every 100 people with private health insurance declined by 22%, from 169.5 to 134.3, the study found….
Biologic Spending & Price Trends
Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…
Increased Risk of Inflammatory Arthritis with Hidradenitis Suppurativa
NEW YORK (Reuters Health)—Patients with hidradenitis suppurativa face an increased risk of developing inflammatory arthritis, according to findings from a claims database. “We observed increased risks of developing ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (RA) among patients with hidradenitis suppurativa when compared with those without hidradenitis suppurativa,” says Maria C. Schneeweiss, MD, of Brigham…
The ACR to Host the 22nd PANLAR Pan-American Congress of Rheumatology
The 22nd PANLAR Pan-American Congress of Rheumatology will provide rheumatologists access to a cutting-edge scientific program and the opportunity to meet colleagues from all over the Americas…
Denosumab Tied to Infection Risk
NEW YORK (Reuters Health)—The osteoporosis drug denosumab is associated with a higher incidence of serious infections compared with placebo, but the risk is similar to comparator drugs, a systematic review and meta-analysis reveals. Talia Diker-Cohen, MD, PhD, of Tel Aviv University, and colleagues searched the literature through May 2019 for randomized controlled trials of denosumab…
Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020
NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…
Malignancy Risk Varies with Treatment in Systemic Necrotizing Vasculitis
NEW YORK (Reuters Health)—The risk of malignancy in patients with systemic necrotizing vasculitis varies according to the treatment received, according to an analysis of five randomized controlled trials. Previous studies reported an increased risk of malignancy in patients with systemic necrotizing vasculitis, and a more recent study from the European Vasculitis Study Group, based on…
One-Third of U.S. Healthcare Spending Is Administrative Costs
(Reuters Health)—U.S. insurers and providers spent more than $800 billion in 2017 on administration, or nearly $2,500 per person—more than four times the per-capita administrative costs in Canada’s single-payer system, a new study finds. Over one-third of all healthcare costs in the U.S. were due to insurance company overhead and provider time spent on billing,…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 97
- Next Page »